Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset-Reference-Cited by-同舟云学术

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Published:2019-01 Issue:1 Volume:14 Page:99-106
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cho Byoung Chul,Chewaskulyong Busayamas,Lee Ki Hyeong,Dechaphunkul Arunee,Sriuranpong Virote,Imamura Fumio,Nogami Naoyuki,Kurata Takayasu,Okamoto Isamu,Zhou Caicun,Cheng Ying,Cho Eun Kyung,Voon Pei Jye,Lee Jong-Seok,Mann Helen,Saggese Matilde,Reungwetwattana Thanyanan,Ramalingam Suresh S.,Ohe Yuichiro

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

2. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update;Hanna;J Clin Oncol,2017

3. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

4. Erlotinib versus chemotherapy as first-line treatment for patients withadvanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China;Wu;Asia Pac J Clin Oncol,2012

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma;2024-09-13

2. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

3. Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis;BMJ Supportive & Palliative Care;2024-08-19

4. Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis;Cell Biology International;2024-08-13

5. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07